The Manila Times3d
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
"We are excited to initiate the Phase 3 study and we believe that Piclidenoson's oral dosage and excellent safety record, ...
Morningstar4d
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
Upon positive conclusion of the Phase 3 program, the Company plans to submit a New Drug Application (NDA) to the U.S. FDA and Marketing Authorization Plan (MAA) to the EMA. Piclidenoson is a novel ...
Can-Fite BioPharma Ltd.: Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) ...
Alvotech Reports Record Results for 2024 and Provides Business Update
Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...
AZoLifeSciences on MSN3d
The Role of Dissolution Testing in Supplement Development
Dissolution testing in drug development evaluates supplement bioavailability and stability, crucial for maintaining quality ...
pharmaphorum4d
Meeting pharmacovigilance standards in the US and Europe
While the FDA, European Medicines Agency (EMA), and the UK’s Medicines and ... the failure or significant delay to submit safety variations to update the safety sections of Summaries of Product ...